A biomarker is a biological characteristic of a person that can be measured and serves to indicate something about the person’s health. For example, blood sugar levels are a biomarker for diabetes. Biomarkers are found in blood, other body fluids, or tissues and can indicate normal function or the presence of diseases including cancer. In cancer treatments, biomarkers can be used to match a patient to targeted treatments that are more likely to be effective in preventing toxicity of standard therapies. Examples of cancer biomarkers include presence of certain genetic mutations.



Biopsies involve the removal of tissue from a body and the examination of what was removed. In cancer clinical trials, biopsies can help researchers understand a patient’s specific cancer, if a certain treatment might be more likely to work and how the patient is responding to therapy.


Gene Mutation

A gene mutation is a permanent alteration in the DNA sequence that makes up a gene, such that the sequence differs from what is found in most people. Some gene mutations are inherited (germline mutations). Some gene mutations happen over time (acquired mutations) due to damage such as exposure to tobacco smoke, ultraviolet light, viruses or may happen spontaneously as we age. Gene mutations happen often, but the body is typically able to correct most of them. Often multiple mutations are needed before a cell becomes cancerous.



Every cancer clinical trial is overseen by a federally-regulated IRB (Institutional Review Board). The IRB is a committee that helps to protect the interests and welfare of particpants. They also ensure participant confidentially and privacy.


Inclusion Criteria

Each clinical trial looks for patients whose health and cancer meet a certain set of traits defined by the study. Inclusion criteria help to ensure that a specific treatment is right and safe for the patient.


Exclusion Criteria

Each clinical trial has a list of conditions or characteristics defined in the study exclusion criteria that would disqualify a patient from participation. These criteria help to ensure that a specific treatment is right and safe for the patient.


Informed Consent

Informed consent is the process of ensuring that a clinical trial participant is fully aware of key aspects of a study and how it will impact them personally. An informed consent document outlines the details about the treatment being studied, potential risks and benefits, as well as the patient’s responsibilities as part of a clinical trial. Each clinical trial participant – or their legal guardian in the case of a pediatric patient – must sign an informed consent document to participate in a clinical trial.



A placebo is an inactive drug or treatment typically used by a control group in a study. It’s important to note that placebos are rarely used in cancer clinical trials. If they are used, they are typically combined with the standard treatment a patient would receive if they were not in a trial.


Serial Biopsies

Serial biopsies are a set of biopsies taken at different times during the course of therapy. A series of biopsies provides insight on whether a treatment is working and how the cancer changes in response to the therapy. Often, this is some of the most valuable data collected during a clinical trial.


Standard Of Care

The standard of care or standard treatment is the therapy that is widely used to treat a specific type and stage of cancer.


Tissue Banking

Tissue banking securely and privately stores tissue samples from biopsies for use in future studies. As science advances, new questions can be answered by examining banked tissues in different ways. This speeds cancer research as the process of reexamining banked tissue is much more efficient than collecting new samples from patients.


Trial Phases

Cancer clinical trials are conducted in a series of steps—or phases from 1 to 4. The phase of the trial indicates the focus of the trial from whether a treatment is safe, to long term side effects or benefits of a treatment.


Take The Next Step: Find A Trial


Stand Up To Cancer is pleased to connect interested parties with EmergingMed, a free and confidential trial matching service that will help guide you through a search and referral process to find a clinical trial that may be right for you.

Call Toll-Free (877.769.4829)

Monday – Friday 9:00 am – 6:00 pm ET
Se Habla Español


Fill Out The Form Below

EmergingMed is a third-party service provider and is not affiliated with SU2C in any way. SU2C disclaims any and all liability, including any express or implied warranties, whether oral or written, for such third-party services. By using such services, you acknowledge that no representation has been made by SU2C as to the fitness of the third-party services for your intended purpose.


Fill out an online questionnaire to immediately identify clinical trials that may match your specific diagnosis, stage and treatment history.

For over a decade, EmergingMed’s clinical navigators have
facilitated clinical trial searches for nearly 500,000 patients.
Learn about Stand Up To Cancer’s SU2C Catalyst® clinical trials.